Board Member
Zevra Therapeutics, Inc. (ZVRA)Equibles does not estimate personal net worth.
Get an email with a short summary when Zevra Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ZVRA alertsNeil F. McFarlane is recorded as CEO and Board Member at Zevra Therapeutics, Inc. (ZVRA). The newest filing on record that lists Neil F. McFarlane as CEO and Board Member at Zevra Therapeutics, Inc. (ZVRA) is dated April 3, 2024. Zevra Therapeutics, Inc. reported in an 8-K filed October 10, 2023 that Neil F. McFarlane was appointed member of the Board, effective October 10, 2023. Zevra Therapeutics, Inc. reported in an 8-K filed October 10, 2023 that Neil F. McFarlane was appointed President and Chief Executive Officer, effective October 10, 2023. The proxy statement of Zevra Therapeutics, Inc. reports total compensation of $3,782,042 for Neil F. McFarlane in fiscal 2025, including a base salary of $729,167. Disclosed compensation is on record for 3 fiscal years. Neil F. McFarlane has spoken on 13 earnings calls and 3 other investor events across 1 company, most recently for Zevra Therapeutics, Inc. on November 3, 2026. Zevra Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Zevra Therapeutics, Inc. includes Christal M.M. Mickle (CEO), Richard W. Pascoe (CEO), Matthew R. Plooster (Chairman) and 7 others.
“Concurrently with his appointment as President and Chief Executive Officer, Mr. McFarlane was appointed to serve as a member of the Board.”
“On October 7, 2023, the Board of Directors (the "Board") of Zevra Therapeutics, Inc. (the "Company") appointed Neil F. McFarlane to serve as the Company's President and Chief Executive Officer, effective October 10, 2023.”
“Zebra is a purpose-driven company, redefining what is possible in bringing life-changing therapies to people living with rare diseases. In rare disease, the path is complex, the needs are urgent, and the responsibility is significant.”
“We really appreciate the support of Moving Family. I will be making forward-looking statements, so I'd ask for everybody to take a look at our most recent SEC filings to ensure that you get the most up-to-date information.”
“And we'll be making some forward-looking statements, so take a look at our most recent SEC filings for the most up-to-date information. Yes, we had our earnings last week, and we ended up announcing a very good quarter.”
“Good afternoon, and thank you for joining Zevra's second quarter 2026 financial results and corporate update conference call. Today's call is being recorded and will be available via the investor relations section of the company's website later today.”
“Please take a look at our most recent SEC filings for most up-to-date information and we're really looking forward to having a conversation here post-earnings and getting into some of your questions.”
Start not stated–present
Last confirmed April 3, 2024
Start not stated–present
Last confirmed April 3, 2024
Biotechnology · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Zevra Therapeutics, Inc. (ZVRA) | President, Chief Executive Officer and Director | $729,167 | $3,782,042 |
| 2024 | Zevra Therapeutics, Inc. (ZVRA) | President, Chief Executive Officer and Director | $700,000 | $5,355,059 |
| 2023 | Zevra Therapeutics, Inc. (ZVRA) | President, Chief Executive Officer and Director | $157,500 | $3,445,231 |
